SecurityFOSL / Fossil Group, Inc. (34988V106)
Chairman of the Board & CEOKARTSOTIS KOSTA N
Form 4 Count260
Form 8-K Count63
Form SC 13G/A Count39
Form 10-Q Count20

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fossil Group, Inc.


DateFormTitle
2018-09-10 SC 13G/A FOSL / Fossil Group, Inc. / VANGUARD GROUP INC - null (Passive Investment)
2018-09-10 SC 13G/A FOSL / Fossil Group, Inc. / VANGUARD GROUP INC - null (Passive Investment)
2018-08-09 10-Q FOSL / Fossil Group, Inc. 10-Q (Quarterly Report)
2018-08-08 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2018-06-29 11-K FOSL / Fossil Group, Inc. 11-K
2018-06-26 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SCHEDULE 13G (Passive Investment)
2018-06-26 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SCHEDULE 13G (Passive Investment)
2018-06-15 S-8 FOSL / Fossil Group, Inc. S-8
2018-06-28 LETTER FOSL / Fossil Group, Inc. null
2018-06-28 CORRESP FOSL / Fossil Group, Inc. null
2018-05-28 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2018-05-23 SD FOSL / Fossil Group, Inc. SD
2018-06-28 LETTER FOSL / Fossil Group, Inc. null
2018-06-28 CORRESP FOSL / Fossil Group, Inc. null
2018-05-10 10-Q FOSL / Fossil Group, Inc. 10-Q (Quarterly Report)
2018-05-08 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2018-06-28 LETTER FOSL / Fossil Group, Inc. null
2018-04-12 DEFA14A FOSL / Fossil Group, Inc. DEFA14A
2018-04-12 DEF 14A FOSL / Fossil Group, Inc. DEF 14A
2018-03-02 10-K FOSL / Fossil Group, Inc. 10-K (Annual Report)
2018-02-14 SC 13G FOSL / Fossil Group, Inc. / Connor, Clark & Lunn Investment Management Ltd. - FORM 13G DEC 31 2017 (Passive Investment)
2018-02-14 SC 13G FOSL / Fossil Group, Inc. / Connor, Clark & Lunn Investment Management Ltd. - FORM 13G DEC 31 2017 (Passive Investment)
2018-02-13 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2018-02-13 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SCHEDULE 13G (Passive Investment)
2018-02-13 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SCHEDULE 13G (Passive Investment)
2018-02-13 SC 13G/A FOSL / Fossil Group, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-13 SC 13G/A FOSL / Fossil Group, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-09 SC 13G FOSL / Fossil Group, Inc. / Contrarius Investment Management Ltd - ACQUISITION OF BENEFICIAL OWNERSHIP (Passive Investment)
2018-02-09 SC 13G FOSL / Fossil Group, Inc. / Contrarius Investment Management Ltd - ACQUISITION OF BENEFICIAL OWNERSHIP (Passive Investment)
2018-02-09 SC 13G/A FOSL / Fossil Group, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-09 SC 13G/A FOSL / Fossil Group, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-01-30 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2018-01-23 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SC 13G (Passive Investment)
2018-01-23 SC 13G FOSL / Fossil Group, Inc. / CLASSIC FUND MANAGEMENT AKTIENGESELLSCHAFT - SC 13G (Passive Investment)
2018-01-19 SC 13G/A FOSL / Fossil Group, Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2018-01-19 SC 13G/A FOSL / Fossil Group, Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2017-11-09 10-Q FOSL / Fossil Group, Inc. 10-Q (Quarterly Report)
2017-11-07 8-K FOSL / Fossil Group, Inc. 8-K (Current Report)
2017-11-10 LETTER FOSL / Fossil Group, Inc. ER
2017-11-10 CORRESP FOSL / Fossil Group, Inc. ESP
2017-11-10 LETTER FOSL / Fossil Group, Inc. ER
2017-09-05 8-K Fossil Group 8-K (Current Report/Significant Event)
2017-08-14 8-K Fossil Group 8-K (Current Report/Significant Event)
2017-08-10 10-Q Fossil Group 10-Q (Quarterly Report)
2017-08-08 8-K Fossil Group (Current Report/Significant Event)
2017-07-27 SC 13G Fossil Group SC 13G (Passive Acquisition of More Than 5% of Shares)
2017-07-27 SC 13G Fossil Group SC 13G (Passive Acquisition of More Than 5% of Shares)
2017-07-26 8-K Fossil Group 8-K (Current Report/Significant Event)
2017-07-25 SC 13G Fossil Group SC 13G (Passive Acquisition of More Than 5% of Shares)
2017-07-25 SC 13G Fossil Group SC 13G (Passive Acquisition of More Than 5% of Shares)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 34988V106